BMY Stock Forecast: Bristol Myers Squibb Co. Price Predictions for 2026-2027
The 28 Wall Street analysts covering Bristol Myers Squibb Co. hold a median 12-month price target of $66 — +11.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 94 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Bristol Myers Squibb Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (55): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BMY stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BMY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.4% from it.
Of the 20 most recent actions, 10 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Oct 2026 | Morgan Stanley | Maintains | Underweight | $41 → $40 |
| 26 Oct 2026 | Piper Sandler | Maintains | Overweight | $82 → $78 |
| 13 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $65 → $60 |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Neutral | $59 → $53 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Underweight | $40 → $41 |
| 5 Oct 2026 | Leerink Partners | Downgrade | Market Perform | $73 → $59 |
| 16 Sept 2026 | Piper Sandler | Reiterates | Overweight | $75 → $82 |
| 10 Sept 2026 | HSBC | Maintains | Hold | $60 → $65 |
| 5 Aug 2026 | Argus Research | Upgrade | Buy | $75 |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $66 → $70 |
| 31 July 2026 | Cantor Fitzgerald | Maintains | Neutral | $54 → $59 |
| 31 July 2026 | Guggenheim | Maintains | Buy | $72 → $75 |
| 31 July 2026 | JP Morgan | Maintains | Overweight | $67 → $73 |
| 31 July 2026 | RBC Capital | Maintains | Sector Perform | $60 → $64 |
| 31 July 2026 | Truist Securities | Reiterates | Buy | $65 → $70 |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | $60 → $65 |
| 10 July 2026 | B of A Securities | Maintains | Buy | $67 → $66 |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | $54 |
| 9 Apr 2026 | B of A Securities | Maintains | Buy | — |
| 8 Apr 2026 | Cantor Fitzgerald | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BMY.
This page is one stock. Monday covers all of them.
BMY appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BMY vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Bristol Myers Squibb Co. returned +33.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BMY analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 13.3×
- Price / sales
- 2.4×
- Price / book
- 5.2×
- EV / EBITDA
- 8.3×
Cheaper than 61% of US stocks
Cheaper than 42% of US stocks
Cheaper than 17% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- 6.9%
- Earnings growth (YoY)
- −1.8%
- Gross margin
- 71.3%
- Operating margin
- 32.4%
- Net margin
- 18.5%
Higher than 46% of US stocks
Higher than 34% of US stocks
Higher than 84% of US stocks
Higher than 89% of US stocks
Higher than 80% of US stocks
- Return on equity
- 44.0%
- Return on assets
- 10.9%
- Dividend yield
- 4.2%
Higher than 92% of US stocks
Higher than 93% of US stocks
Higher than 75% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bristol Myers Squibb Co. has a market value of $119.3B and an enterprise value of $151.5B.
Revenue in the twelve months to 30 June 2026: $49.2B. The latest quarter grew 5.7% year on year.
Net income over the same four quarters: $9.3B, a 18.9% net margin.
Diluted earnings per share, trailing twelve months: $4.54.
Free cash flow in the twelve months to 30 June 2026: $11.4B, after $1.3B of capital spending.
Bristol Myers Squibb Co. spent $5.1B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 13.3×; forward P/E: 8.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 4.25%, paying out 56% of earnings.
Bristol Myers Squibb Co. employs 32,500 people — $1.5M of revenue per employee.
Data provided by Twelve Data
BMY and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BMY’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Bristol Myers Squibb Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BMY
What is the BMY stock price forecast for 2026-2027?
The 28 Wall Street analysts covering Bristol Myers Squibb Co. have a median 12-month price target of $66, with estimates ranging from $40 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BMY stock a buy right now?
Of the 28 analysts covering Bristol Myers Squibb Co., 10 rate it a Buy, 17 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bristol Myers Squibb Co. 94 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BMY?
As at 21 Nov 2026, Bristol Myers Squibb Co. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
Will BMY stock go up?
No one can know that. What the data says: the median 12-month target from 28 analysts implies +11.4% from the last close, and Ticker Nerd's factor model ranks Bristol Myers Squibb Co. 94 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BMY stock forecast for 2030?
No analyst covering Bristol Myers Squibb Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $80 over the next 12 months.
How has BMY stock performed over the past year?
Bristol Myers Squibb Co. returned +33.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bristol Myers Squibb Co. do?
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions.
About Bristol Myers Squibb Co.
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions. Its portfolio includes small-molecule drugs, biologics, and cell therapies, reflecting a broad approach to advanced treatment design and delivery. The company supports healthcare systems through research-driven products used in hospitals, specialty clinics, and outpatient care settings around the world. Bristol-Myers Squibb Company plays an important role in the pharmaceutical market by providing therapies aimed at difficult-to-treat illnesses and by maintaining a diversified pipeline and product mix across multiple disease categories.
CEO Dr. Christopher S. Boerner Ph.D. · 32,500 employees · United States · https://www.bms.com